USANA Health Sciences (NYSE:USNA) Insider Joshua Foukas Sells 3,791 Shares of Stock

USANA Health Sciences, Inc. (NYSE:USNA) insider Joshua Foukas sold 3,791 shares of the stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $19.82, for a total value of $75,137.62. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Joshua Foukas also recently made the following trade(s):

• On Friday, February 20th, Joshua Foukas sold 4,461 shares of USANA Health Sciences stock. The stock was sold at an average price of $21.34, for a total value of $95,197.74.

USANA Health Sciences Price Performance

Shares of USNA opened at $19.00 on Friday. USANA Health Sciences, Inc. has a 12 month low of $16.60 and a 12 month high of $38.32. The stock has a fifty day moving average price of $18.45 and a 200 day moving average price of $19.70. The company has a market cap of $350.74 million, a P/E ratio of 40.43, a PEG ratio of 0.76 and a beta of 0.77.

USANA Health Sciences (NYSE:USNA) last posted its earnings results on Tuesday, May 5th. The company reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.17. USANA Health Sciences had a return on equity of 6.21% and a net margin of 0.96%.The company had revenue of $250.22 million for the quarter, compared to analysts’ expectations of $240.99 million. USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. As a group, research analysts anticipate that USANA Health Sciences, Inc. will post 2.12 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have commented on the stock. Wall Street Zen cut shares of USANA Health Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Weiss Ratings reaffirmed a “sell (d)” rating on shares of USANA Health Sciences in a report on Friday, March 27th. Finally, Zacks Research downgraded USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 22nd. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Reduce”.

Hedge Funds Weigh In On USANA Health Sciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Hsbc Holdings PLC increased its position in shares of USANA Health Sciences by 68.7% during the 1st quarter. Hsbc Holdings PLC now owns 22,493 shares of the company’s stock valued at $393,000 after purchasing an additional 9,159 shares during the period. DGS Capital Management LLC acquired a new stake in shares of USANA Health Sciences in the first quarter valued at $208,000. Strs Ohio lifted its holdings in shares of USANA Health Sciences by 12.7% in the first quarter. Strs Ohio now owns 31,000 shares of the company’s stock valued at $542,000 after buying an additional 3,500 shares during the period. Inspire Investing LLC boosted its stake in USANA Health Sciences by 22.6% during the first quarter. Inspire Investing LLC now owns 29,362 shares of the company’s stock valued at $513,000 after buying an additional 5,419 shares in the last quarter. Finally, State of Tennessee Department of Treasury boosted its stake in USANA Health Sciences by 307.8% during the fourth quarter. State of Tennessee Department of Treasury now owns 29,290 shares of the company’s stock valued at $636,000 after buying an additional 22,108 shares in the last quarter. 54.25% of the stock is owned by institutional investors.

Key Stories Impacting USANA Health Sciences

Here are the key news stories impacting USANA Health Sciences this week:

• Positive Sentiment: USANA reported a strong Q1 result, with earnings per share coming in well above expectations and revenue also beating estimates, reinforcing the view that the business is still generating better-than-expected profitability. USANA Health Sciences, Inc. Just Recorded A 78% EPS Beat: Here’s What Analysts Are Forecasting Next
• Positive Sentiment: Sidoti raised its FY2026 EPS estimate for USANA, a sign that analysts are becoming more optimistic about the company’s earnings outlook. Sidoti EPS estimate increase
• Positive Sentiment: USANA was upgraded to Zacks Rank #2 (Buy), which may support near-term buying interest as the stock screens better on earnings-estimate momentum. USANA Health (USNA) Upgraded to Buy: What Does It Mean for the Stock?
• Neutral Sentiment: USANA received a USA TODAY Top Workplaces award, which is a positive branding and culture headline but is unlikely to materially affect earnings by itself. USANA’s People-First Culture Earns Spot on USA TODAY Top Workplaces List
• Neutral Sentiment: An insider sale by Joshua Foukas may create some caution, but the transaction was relatively small and does not necessarily signal a fundamental problem. Joshua Foukas insider sale

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah?based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight?management products and skin?care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical?grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.